{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:16Z","timestamp":1787117116339,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated insulin-like growth factor-1 (IGF-1) levels are associated with earlier pubertal onset and accelerated bone maturation. However, the effect of IGF-1 increases during growth hormone (GH) therapy on bone age (BA) advancement across different etiologies of short stature remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter observational study included 1,944 children with idiopathic growth hormone deficiency (IGHD), idiopathic short stature (ISS), or small for gestational age (SGA) enrolled in the LG Growth Study registry between 2020 and 2024. IGF-1 standard deviation score (SDS), auxological parameters, GH dose, and BA were assessed during GH therapy. BA advancement was defined as the first occurrence of a BA-to-chronological age ratio (BA\/CA) &amp;gt;1 during follow-up. Cox proportional hazards regression models were used to evaluate the association between IGF-1 SDS and BA advancement, with additional multivariable adjustment for potential clinical confounders. Additional subgroup analyses according to age, sex, diagnosis, and GHD severity were performed. A sensitivity analysis using BA\/CA &amp;gt;1.2 was also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Each 1-unit increase in IGF-1 SDS was associated with a higher risk of BA advancement in the overall cohort (hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.15\u20131.33, p&amp;lt;0.001), with consistent associations in males and females. Compared with IGHD, children with ISS (HR 1.63, 95% CI 1.26\u20132.11) and SGA (HR 2.15, 95% CI 1.82\u20132.55) showed significantly increased risks of BA advancement. Additional analyses stratified by age, GHD severity, and pubertal initiation showed consistent findings. Sensitivity analysis using BA\/CA &amp;gt;1.2 confirmed the association between IGF-1 SDS elevation and significant BA advancement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increases in IGF-1 SDS during GH therapy are independently associated with accelerated bone maturation in children with short stature, particularly in those born SGA. These findings remained consistent across multiple subgroups and sensitivity analyses, supporting the importance of individualized GH dosing with careful monitoring of IGF-1 levels and skeletal maturation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1843625","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:30Z","timestamp":1787114370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated IGF-1 levels are associated with accelerated bone age advancement during growth hormone therapy in children: a multicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jungmin","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Jeju National University Hospital","place":["Jeju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwalrim","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Soonchunhyang University Cheonan Hospital","place":["Cheonan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghwan","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Severance Children\u2019s Hospital, Endocrine Research Institute, Yonsei University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Wook","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Severance Children\u2019s Hospital, Endocrine Research Institute, Yonsei University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000528662","article-title":"Higher prepubertal IGF-1 concentrations associated with earlier pubertal tempo in both sexes","volume":"96","author":"Baier","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.05.007","article-title":"The regulation of reproductive neuroendocrine function by insulin and insulin-like growth factor-1 (IGF-1)","volume":"35","author":"Wolfe","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2022.02.004","article-title":"Growth variations with opposite clinical outcomes and the emerging role of IGF-1","volume":"33","author":"Papadimitriou","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.5114\/reum\/170244","article-title":"The influence of growth hormone deficiency on bone health and metabolism","volume":"61","author":"Wydra","year":"2023","journal-title":"Reumatologia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6065\/apem.2018.23.1.43","article-title":"Design of the long-term observational cohort study with recombinant human growth hormone in Korean children: LG Growth Study","volume":"23","author":"Chung","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clinbiochem.2011.09.016","article-title":"Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents","volume":"45","author":"Hyun","year":"2012","journal-title":"Clin Biochem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2018.61.5.135","article-title":"The 2017 Korean national growth charts for children and adolescents","volume":"61","author":"Kim","year":"2018","journal-title":"Korean J Pediatr"},{"key":"B8","volume-title":"Radiologic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959"},{"key":"B9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000438841","article-title":"Definition, diagnosis and treatment of pubertal delay in the general population","volume":"29","author":"Juul","year":"2016","journal-title":"Endocr Dev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000110565","article-title":"The role of the GH\u2013IGF-I axis in the timing of puberty","volume":"68","author":"Heger","year":"2007","journal-title":"Horm Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1800247","article-title":"Evidence supporting dual, IGF-I-dependent and -independent roles for growth hormone in promoting longitudinal bone growth","volume":"180","author":"Wang","year":"2004","journal-title":"J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000088791","article-title":"Endocrine regulation of the growth plate","volume":"64","author":"Nilsson","year":"2005","journal-title":"Horm Res Paediatr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1023\/a:1020905725012","article-title":"Growth hormone insensitivity (Laron syndrome)","volume":"3","author":"Laron","year":"2002","journal-title":"Rev Endocr Metab Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/mp.54.5.311","article-title":"Insulin-like growth factor 1 (IGF-1): a growth hormone","volume":"54","author":"Laron","year":"2001","journal-title":"Mol Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4158\/EP15939.RA","article-title":"Lessons from 50 years of study of Laron syndrome","volume":"21","author":"Laron","year":"2015","journal-title":"Endocr Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1373.2000.22349.x","article-title":"Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre\/loxP system","volume":"223","author":"Liu","year":"2000","journal-title":"Proc Soc Exp Biol Med"},{"key":"B17","article-title":"Serum IGF-I and IGFBP-3 concentrations in a healthy pediatric population","volume":"153","author":"Soriano-Guillen","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci0215463","article-title":"Circulating levels of IGF-1 regulate bone growth and density","volume":"110","author":"de Zegher","year":"2002","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1210\/er.2002-0033","article-title":"Systemic and local regulation of the growth plate","volume":"24","author":"van der Eerden","year":"2003","journal-title":"Endocr Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.1.8293","article-title":"The role of microRNAs in growth plate development","volume":"24","author":"de Zegher","year":"2020","journal-title":"J Orthop Translat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000360857","article-title":"Genetic causes of short stature","volume":"64","author":"Dauber","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1506","article-title":"Genetic evaluation of short stature","volume":"99","author":"Dauber","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2005.10.010","article-title":"Growth hormone therapy for children born small for gestational age","volume":"90","author":"de Zegher","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.5.1887","article-title":"High-dose growth hormone treatment in short children born small for gestational age","volume":"92","author":"Karlberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7324","article-title":"Normal growth and development in the absence of hepatic insulin-like growth factor I","volume":"96","author":"Upners","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000089324","article-title":"Timing and dosage of growth hormone treatment in children born small for gestational age","volume":"30","author":"Hokken-Koelega","year":"2016","journal-title":"Endocr Dev"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1203\/01.PDR.0000148716.71231.81","article-title":"Final height in short children born small for gestational age treated with growth hormone","volume":"57","author":"Dahlgren","year":"2005","journal-title":"Pediatr Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1203\/01.pdr.0000148716.71231.81","article-title":"Final height in short children born small for gestational age treated with growth hormone","volume":"57","author":"Dahlgren","year":"2005","journal-title":"Pediatr Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3970","article-title":"Consensus statement on idiopathic short stature","volume":"93","author":"Rappaport","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-15-0873","article-title":"Growth hormone therapy in children: a review","volume":"12","author":"Allen","year":"2002","journal-title":"Growth Hormone IGF Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.36.6.940","article-title":"Growth hormone therapy safety update","volume":"101","author":"Yakar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1471","article-title":"Observed and predicted growth responses in prepubertal children with growth disorders","volume":"95","author":"Ranke","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents","volume":"86","author":"Nakamichi","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone\u2014past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1210\/jc.2006-2017","article-title":"IGF-I and growth hormone treatment in children: benefits and safety","volume":"67","author":"Clayton","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2017","article-title":"Management of the child born small for gestational age through to adulthood","volume":"92","author":"Grimberg","year":"2007","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:41Z","timestamp":1787114381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1843625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1843625"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1843625","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1843625"}}